Establishing an Anemia Clinic for Optimal Erythropoietic-Stimulating Agent Use in Hematology-Oncology Patients

Erythropoietic-stimulating agent (ESA) therapy has significantly impacted the management of chemotherapy-induced anemia (CIA) by decreasing the number of red blood cell transfusions required by patients with cancer. However, managing these patients with ESA therapy has become increasingly difficult since the release of the Centers for Medicare & Medicaid Services' new National Coverage Determination document because of the disparities between this document and recommendations from expert-reviewed national clinical guidelines on the treatment of anemia. This article describes a collaborative practice agreement between pharmacists and physicians as one approach to managing CIA in hematology-oncology patients in an anemia clinic. The goal of the pharmacist-managed anemia clinic is to improve patient satisfaction and clinical outcomes associated with the treatment of CIA. This article describes the rationale for the clinic and discusses its design and implementation in managing ESA, iron, folate, and vitamin B12 therapy for CIA in hematology-oncology patients. The pharmacist's role is justified in this clinic model through increased adherence to evidence-based practice guidelines and decreased costs associated with ESA therapy.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Jeffrey A. Gilreath, PharmD, Huntsman Cancer Institute, 1950 Circle of Hope, Suite 2110, Salt Lake City, UT 84112. E-mail: jeffrey.gilreath@hci.utah.edu
  • 1.

    LudwigHVan BelleSBarrett-LeeP. The European Cancer in Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer2004;40:22932306.

    • Search Google Scholar
    • Export Citation
  • 2.

    RodgersGMBeckerPSBennettCL. NCCN Clinical Practice Guidelines in Oncology: Cancer- and Treatment-Related Anemia version 2.2008. Available at: http://www.nccn.org/professionals/physician_gls/PDF/anemia.pdf. Accessed April 11 2008.

    • Search Google Scholar
    • Export Citation
  • 3.

    AuerbachMBallardHTroutJR. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol2004;22:13011307.

    • Search Google Scholar
    • Export Citation
  • 4.

    HenryDHDahlNVAuerbachM. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist2007;12:231242.

    • Search Google Scholar
    • Export Citation
  • 5.

    BrugnaraCColellaGMCreminsJC. Effects of subcutaneous recombinant human erythropoietin in normal subjects: development of decreased reticulocyte hemoglobin content and iron-deficient erythropoiesis. J Lab Clin Med1994;123:660667.

    • Search Google Scholar
    • Export Citation
  • 6.

    BamgbolaOFKaskelF. Role of folate deficiency on erythropoietin resistance in pediatric and adolescent patients on chronic dialysis. Pediatr Nephrol2005;20:16221629.

    • Search Google Scholar
    • Export Citation
  • 7.

    BreenCPMacdougallIC. Correction of epoetin-resistant megaloblastic anaemia following vitamin B12 and folate administration. Nephron1999;83:374375.

    • Search Google Scholar
    • Export Citation
  • 8.

    GabriloveJLCleelandCSLivingstonRB. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to threetimes-weekly dosing. J Clin Oncol2001;19:28752882.

    • Search Google Scholar
    • Export Citation
  • 9.

    SchwartzbergLSYeeLKSenecalFM. A randomized comparison of every-2-week Darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer. Oncologist2004;9:696707.

    • Search Google Scholar
    • Export Citation
  • 10.

    Procrit [package insert]. Raritan, NJ: Ortho Biotech Products, L.P.; 2005.

  • 11.

    Aranesp [package insert]. Thousand Oaks, CA: Amgen Inc.; 2006.

  • 12.

    HedenusMBirgegårdGNäsmanP. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia2007;21:627632.

    • Search Google Scholar
    • Export Citation
  • 13.

    BastitLVandebroekAAltintasS. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alpha administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol2008;26:16111608.

    • Search Google Scholar
    • Export Citation
  • 14.

    PedrazzoliPFarrisADel PreteS. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol2008;26:16191625.

    • Search Google Scholar
    • Export Citation
  • 15.

    AuerbachMHenryDH. Increased importance of intravenous iron in chemotherapy-induced anemia. J Clin Oncol2007;25:21452146.

  • 16.

    Premier's Perspective Comparative Database [database online]. Charlotte, NC: Premier Inc.

  • 17.

    Leyland-JonesB. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol2003;4:459460.

  • 18.

    HenkeMLaszigRRűbeC. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomized, double-blind, placebo-controlled trial. Lancet2003;362:12551260.

    • Search Google Scholar
    • Export Citation
  • 19.

    WrightJRUngYCJulianJA. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol2007;25:10271032.

    • Search Google Scholar
    • Export Citation
  • 20.

    HedenusMAdrianssonMSan MiguelJ. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol2003;122:394403.

    • Search Google Scholar
    • Export Citation
  • 21.

    BennettCLSilverSMDjulbegovicB. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA2008;299:914924.

    • Search Google Scholar
    • Export Citation
  • 22.

    WilkinsonJ. Describing the usage patterns and outcomes of hematopoietic agents at the Huntsman Cancer Institute. Presented at the Western States Residency Conference; May 2004; Asilomar CA.

    • Search Google Scholar
    • Export Citation
  • 23.

    KuoGMBuckleyTEFitzsimmonsDSSteinbauerJR. Collaborative drug therapy management services and reimbursement in a family medicine clinic. Am J Health Syst Pharm2004;61:343-354.

    • Search Google Scholar
    • Export Citation
  • 24.

    AnsellJHirshJPollerL. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest2004;126(3 Suppl):204S233S.

    • Search Google Scholar
    • Export Citation
  • 25.

    GrayDRGarabedian-RuffaloSMChretienSD. Cost-justification in a clinical pharmacist-managed anticoagulation clinic. Ann Pharmacother2007;41:496501.

    • Search Google Scholar
    • Export Citation
  • 26.

    AdamsonRBaribeaultDGriffithN. Contemporary growth factor management: three institutional perspectives. Therapeutic Insights and Review2006;41(Suppl 1):114.

    • Search Google Scholar
    • Export Citation
  • 27.

    GlaspyJBukowskiRSteinbergD. Impact of therapy of epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice: Procrit Study Group. J Clin Oncol1997;15:1218.

    • Search Google Scholar
    • Export Citation
  • 28.

    CellaD. The Functional Assessment of Cancer Therapy—Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol1997;34(Suppl 2):1319.

    • Search Google Scholar
    • Export Citation
  • 29.

    GroopmanJEItriLM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst1999;91:16161634.

  • 30.

    LeeM. Basic Skills in Interpreting Laboratory Data. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; 2004.

  • 31.

    BeutlerEHoffbrandAVCookJD. Iron deficiency and overload. Hematology2003;1:4061.

  • 32.

    KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Am J Kidney Dis2006;47(5 Suppl 3):S11145.

    • Search Google Scholar
    • Export Citation
  • 33.

    INFeD [package insert]. Morristown, NJ: Watson Pharmaceuticals, Inc.; 2001.

  • 34.

    AnuradhaSSinghNPAgarwalSK. Total dose infusion iron dextran therapy in predialysis chronic renal failure patients. Ren Fail2002;3:307313.

    • Search Google Scholar
    • Export Citation
  • 35.

    AuerbachMChaudryMGoldmanH. Value of methylprednisolone in prevention of arthralgia-myalgia syndrome associated with total dose infusion of iron dextran: a double-blind, randomized trial. J Lab Clin Med1998;131:257260.

    • Search Google Scholar
    • Export Citation
  • 36.

    Ferrlecit [package insert]. Florham Park, NJ: Schein Pharmaceuticals, Inc.; 2001.

  • 37.

    Venofer [package insert]. Shirley, NY: American Regent Laboratories, Inc.; 2001.

  • 38.

    ChandlerGHarchowalJMacdougallIC. Intravenous iron sucrose: establishing a safe dose. Am J Kid Dis2001;38:988991.

  • 39.

    DeicherRZiaiFCohenG. High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int2003;64:728736.

    • Search Google Scholar
    • Export Citation
  • 40.

    SilversteinSBRodgersGM. Parenteral iron therapy options. Am J Hem2004;76:7478.

  • 41.

    Folic acid tablets USP 1 mg [package insert]. Corona, CA: Watson Laboratories, Inc.; 2005.

  • 42.

    SchifflHLangS. Folic acid deficiency modifies the haematopoietic response to recombinant human erythropoietin in maintenance dialysis patients. Nephrol Dial Transplant2006;21:133137.

    • Search Google Scholar
    • Export Citation
  • 43.

    BreenCPMacdougallIC. Correction of epoetin-resistant megaloblastic anaemia following vitamin B12 and folate administration. Nephron1999;83:374375.

    • Search Google Scholar
    • Export Citation
  • 44.

    KuzminskiAMDel GiaccoEJAllenRH. Effective treatment of cobalamin deficiency with oral cobalamin. Blood1998;92:11911198.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 78 74 17
PDF Downloads 22 22 3
EPUB Downloads 0 0 0